DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/wk4s3p/prostate_cancer) has announced the addition of the "Prostate Cancer Drug Pipeline Update 2013" report to their offering.
The prostate cancer market is reaching maturity, and major players' sales have been eroded by the launch of various LHRH agonist depot formulations. Safety concerns with AstraZeneca's Casodex (bicalutamide) have also seen a significant proportion of physicians switching to alternatives. Establishing the optimal timing of antihormonal therapy will provide the key to market growth.
There are today 342 companies plus partners developing 409 drugs targeting prostate cancer in development. In addition, there are 6 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 180 drugs. Prostate Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 273 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date, 263 out of the 267 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drug targets are further categorized on in the software application by 65 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Drug Pipeline Update at a Glance
Investigators
Includes more than 342 principal companies plus their collaborators. There is direct access from inside the application to web pages of all principal companies.
Indications
Included prostate cancer drugs are also in development for 209 other indications, where of 112 are different cancer indications.
Targets
Mutations
All targets are cross-referenced with the Catalogue of Somatic Mutations in Cancer (COSMIC). It is designed to store and display somatic mutation information and related details and contains information relating to human cancers. To date, 263 out of the 267 studied drug targets so far have been recorded with somatic mutations, and the software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information.
Biological Structures
The identity of available biological structures on 188 drug targets was retrieved from the RCSB Protein Databank for you to easily review the 3591 structures available today among drug targets.
For more information visit http://www.researchandmarkets.com/research/wk4s3p/prostate_cancer
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
